SPONSOR
Peking University Cancer Hospital & Institute
Total Trials
5
Recruiting
5
Phases
Phase 1, Phase 2, EARLY_Phase 1
Conditions studied: SCLC, Extensive StageUrothelial CarcinomaRectal CancerNon-Small Cell Lung CancerKidney Cancers
Peking University Cancer Hospital & Institute is a clinical research sponsor with 5 registered studies on ClinicalTrials.gov, of which 5 are actively recruiting participants. Research covers conditions including SCLC, Extensive Stage, Urothelial Carcinoma, Rectal Cancer, Non-Small Cell Lung Cancer.
The trial portfolio spans Phase 1, Phase 2, EARLY_Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Peking University Cancer Hospital & Institute
How many clinical trials has Peking University Cancer Hospital & Institute sponsored?
ClinicalMetric currently tracks 5 clinical trials sponsored by Peking University Cancer Hospital & Institute, of which 5 are actively recruiting participants. These trials cover conditions including SCLC, Extensive Stage, Urothelial Carcinoma, Rectal Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Peking University Cancer Hospital & Institute research focus on?
Peking University Cancer Hospital & Institute clinical trials span SCLC, Extensive Stage, Urothelial Carcinoma, Rectal Cancer, Non-Small Cell Lung Cancer, Kidney Cancers. The research pipeline includes Phase 1, Phase 2, EARLY_Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Peking University Cancer Hospital & Institute clinical trial?
To participate in a Peking University Cancer Hospital & Institute trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Peking University Cancer Hospital & Institute trials with current recruitment status updated daily.
Clinical Trials by Peking University Cancer Hospital & Institute
NCT07413042 Phase 1
Recruiting
A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment
SCLC, Extensive Stage
NCT05321316
Recruiting
Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma
Urothelial Carcinoma
NCT06209099
Recruiting
Organ Preservation First Strategy and Intentional Watch and Wait for MRI Defined Low-risk Rectal Cancer
Rectal Cancer
NCT06849167 Phase 2
Recruiting
Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCLC
Non-Small Cell Lung Cancer
NCT07590310 EARLY_Phase 1
Recruiting
Clinical Application of CAIX-Targeted PET Imaging in Tumors
Kidney Cancers
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology